Psoriasis accounted for a 17.5% share of the global clinical trials within the Immunology therapy area in 2020, registering an increase of 2.4% when compared with the last ten-year average of 15.1% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Psoriasis
Industry sponsored trials held a 67.1% share of all the clinical trials for Psoriasis indication in 2020, registering a decrease of 4.6% when compared with the ten-year average of 71.7%. Non-industry sponsored trials accounted for a 32.9% share in 2020, registering an increase of 4.6% over the ten-year average of 28.3%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Psoriasis trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Psoriasis trials, accounting for a 49.5% share in 2020, when compared with the five-year average of 36.0% and ten-year average of 31.9%.
Europe was at the second position with a 37.9% share in 2020, over the five-year average of 44.9% and ten-year average of 48.6%, followed by North America with a 37.9% share in 2020, as against five-year and ten-year averages of 47.5% and 49.4% respectively.
South and Central America stood fourth with a 4.2% share in 2020, compared with the five-year average of 5.3% and ten-year average of 5.6%, followed by Middle East and Africa with a 3.2% share in 2020, over five-year and ten-year averages of 5.6% and 6.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Psoriasis trials, accounting for a 35.8% share in 2020, as against the five-year average of 43.7% and ten-year average of 44.5%.
China held a 26.3% share in 2020, over the five-year average of 9.7% and ten-year average of 5.5%, followed by Poland with a 17.9% share in 2020, compared with the five-year and ten-year averages of 13.8% and 13.2% respectively.
Germany held a 16.8% share in 2020, as against the five-year average of 24.6% and ten-year average of 26.6%.
Canada held a 12.6% share in 2020, over the five-year and ten-year averages of 18.9% and 20.9% respectively.
Top regions of non-industry sponsored Psoriasis trials
Asia-Pacific was the top region for non-industry sponsored Psoriasis trials, accounting for a 59.2% share in 2020 when compared with the five-year average of 54.9% and ten-year average of 48.2%.
Europe was at the second position with a 20.4% share in 2020, over the five-year and ten-year averages of 19.1% and 22.4% respectively, followed by North America with a 12.2% share in 2020, as against the five-year average of 13.6% and ten-year average of 17.3%.
Middle East and Africa stood at the fourth position with an 8.2% share in 2020, compared with the five-year average of 11.8% and ten-year average of 11.1%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 0.6% and 1.0% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Psoriasis trials, accounting for a 34.7% share in 2020, as against the five-year average of 23.8% and ten-year average of 17.9%.
India held a 16.3% share in 2020, over the five-year average of 22.8% and ten-year average of 16.5%, followed by US with a 12.2% share, compared with the five-year and ten-year averages of 13.1% and 17.0% respectively.
Belgium held an 8.2% share in 2020, as against the five-year average of 2.0% and ten-year average of 1.8%.
Iran held a 6.1% share in 2020, over the five-year average of 10.7% and ten-year average of 8.6%.
Phase I trials lead industry sponsored clinical trials for Psoriasis in 2020
Phase I trials held a 50.0% share of industry sponsored clinical trials for Psoriasis in 2020, over the five-year average of 34.8% and ten-year average of 32.9%.
Phase III trials held a 21.2% share in 2020, as against the five-year average of 27.0% and ten-year average of 27.2%. Phase IV trials held a 15.4% share in 2020, compared with the five-year and ten-year averages of 14.9% and 14.0% respectively.
Phase II trials held a 13.5% share in 2020, over the five-year average of 23.3% and ten-year average of 25.9%.
Phase IV trials lead non-industry sponsored clinical trials for Psoriasis in 2020
Phase IV trials held a 41.2% share of non-industry sponsored clinical trials for Psoriasis in 2020, over the five-year average of 32.1% and ten-year average of 37.9%.
Phase II trials held a 35.3% share in 2020, as against the five-year average of 47.4% and ten-year average of 43.0%. Phase I trials held a 15.7% share, compared with the five-year and ten-year averages of 6.8% and 6.2% respectively.
Phase III trials held a 7.8% share in 2020, over the five-year average of 13.7% and ten-year average of 12.9%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
